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Methodology 
This Good Practice Paper was compiled according to the British Society for Haematology 
(BSH) process at www.b-s-h.org.uk. The BSH produces Good Practice Papers to 
recommend good practice in areas where there is a limited evidence base but for which a 
degree of consensus or uniformity is likely to be beneficial to patient care.  
 
Literature review details 
MEDLINE, EMBASE, DYNAMED, TRIP and NHS EVIDENCE were searched systematically 
for publications in English from 1980 to 2017 using the key words ‘lymphoma’ and ‘mantle 
cell’. References from relevant publications were also searched. Editorials, studies with < 8 
cases and letters were excluded. Conference abstracts have been included if deemed to be 
of particular relevance. 
Review of the manuscript 
Review of the manuscript was performed by the BSH Guidelines Committee Haemato-
oncology Task Force, the BSH Guidelines Committee and the Haemato-oncology sounding 
board of BSH. It was also placed on the members section of the BSH website for comment. 
It has also been reviewed by patient representatives identified by the Lymphoma 





The guidance for the investigation and management of mantle cell lymphoma (MCL), 
published in 2012 (McKay, et al 2012), has been updated and divided into two papers – this 
Good Practice Paper incorporating new information on pathology, in particular molecular 
pathology, and use of positron emission tomography/computed tomography (PET/CT) 
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scanning in staging and response assessment and a Guideline on the Management of MCL 
including new therapeutic options and transplant data (McKay et al 2018). 
MCL is a B cell malignancy with unique biological, pathological and clinical features, 
comprising 3-10% of all non-Hodgkin lymphomas (NHLs) (Swerdlow, et al 1983).  It was 
recognised as a specific entity in the revised European-American classification of lymphoid 
neoplasms (REAL) classification (Harris, et al 1994) and is characterized by the 
chromosomal translocation t(11;14)(q13.3;q32.33), which results in overexpression of the 
cell cycle protein cyclin D1 (Akiyama, et al 1994, Campo, et al 1999).  
 
MCL arises mainly in older adults (median age of presentation is 60-65 years) and has a 
male predominance (Argatoff, et al 1997, Bosch, et al 1998). It often has the worst features 
of both high- and low-grade NHL; an aggressive clinical course, but with a pattern of 
resistant and relapsing disease, rendering it incurable with standard therapy. Historically, the 
median survival was 4-5 years (Herrmann, et al 2009) however this is now in the order of 8-
12 years in younger fitter patients who are able to  tolerate modern intensive therapies 
(Eskelund, et al 2016, Hermine, et al 2016).  
 
A number of studies have described the clinical presentation of MCL (Argatoff, et al 1997, 
Bosch, et al 1998, Tiemann, et al 2005, Zucca, et al 1995). The majority (>90%) of patients 
present with advanced stage (Ann Arbor III-IV) disease. Lymphadenopathy is generally 
widespread at diagnosis, and splenomegaly, bone marrow infiltration and peripheral blood 
involvement are common. Bulk disease at diagnosis and B symptoms are less common. 
Extra nodal involvement is frequent, particularly affecting the gastro-intestinal tract 
(Romaguera, et al 2003) and liver, but infiltration of breast, lung, skin, soft tissue, salivary 
gland and orbit are also seen. Involvement of more than 2 extra nodal sites is seen in 30-
50% of patients (Jares and Campo 2008). Spread to the central nervous system (CNS) can 
occur (see below) but is rare at diagnosis.  
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The clinical course of MCL is heterogeneous. Clinical presentation can correlate with 
pathological sub-type; notably patients with blastoid histology tend to have an aggressive 
clinical course, show refractoriness to treatment and have short survival. In contrast, a 
proportion of cases may present with more indolent disease (Eve, et al 2009, Martin, et al 
2009), characterized by splenomegaly, peripheral blood lymphocytosis, and little or no nodal 
disease (Nodit, et al 2003, Orchard, et al 2003). Survival in this group is of the order of 5-12 
years. Furthermore, the entity of MCL in situ is now recognized, indicating early foci of 
disease in otherwise reactive nodes in asymptomatic patients (Carvajal-Cuenca, et al 2012). 
Outside these extremes, the heterogeneity of the disease and the age of patients in which it 
presents, frequently necessitate an individualized approach.  
 
CNS disease 
Three recent publications (Cheah, et al 2013, Chihara, et al 2015, Conconi, et al 2013) have 
reported a CNS relapse rate between 4.1 and 7.8% with high Ki67 and blastoid histology 
identified as risk factors in multivariate analysis. CNS relapse tends to occur early (median of 
15 to 20 months) and survival is poor (3 to 8 months). A high incidence of leptomeningeal 
disease (91% by flow cytometry) has been reported (Cheah, et al 2013) with parenchymal 
disease being uncommon (12% of cases).  
 
Diagnosis 
Morphology: the diagnosis of MCL may be made by an excision or adequate core biopsy of 
an involved site, endoscopic biopsy, bone marrow trephine biopsy or peripheral blood 
specimen in cases with a leukaemic presentation.  
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In the classical variant (87% of cases), the architecture of the involved lymph node is usually 
completely effaced and is replaced by a diffuse or, less commonly, a nodular infiltrate 
composed of a monomorphic population of small to intermediate sized cells with irregular, 
often cleaved nuclei resembling centrocytes (Argatoff, et al 1997, Swerdlow, et al 1983, 
Tiemann, et al 2005). A mantle zone pattern is seen in a minority of cases (Tiemann, et al 
2005). Vascular hyalinization is often conspicuous and there may also be prominent 
scattered epithelioid histiocytes, especially in cases with a higher proliferation fraction. A 
small cell variant (3.6% of cases) resembling small lymphocytic lymphoma, though lacking 
proliferation centres, is recognized. Other subtypes include the blastoid variant (2.6%), 
morphologically resembling lymphoblastic lymphoma and the pleomorphic variant (5.9%), 
which may be confused on morphological grounds with diffuse large B cell lymphoma 
(DLBCL) (Argatoff, et al 1997, Norton, et al 1995, Ott, et al 1997, Swerdlow, et al 1983, 
Tiemann, et al 2005). Cases with more than one variant pattern may also occur (Tiemann, et 
al 2005). Identical cytomorphological features are identified in biopsies of extranodal sites. In 
trephine biopsy specimens, the infiltrate is most commonly nodular and interstitial and less 
often paratrabecular or diffuse (Argatoff, et al 1997, Cohen, et al 1998). 
 Immunophenotype [formalin-fixed paraffin-embedded (FFPE) tissue]: the majority of MCL 
cases co-express CD20, CD5, BCL2, cyclin D1 and SOX11 and are usually negative for 
CD10, BCL6 and CD23 (Alkan, et al 1995, Argatoff, et al 1997, Sander, et al 2007, Soldini, 
et al 2014, Swerdlow, et al 1995). CD21 highlights a diffuse disorganized network of follicular 
dendritic cells though this may be variable in extent. With modern antibodies to cyclin D1 
(SP4 clone) nuclear expression of cyclin D1 is seen in the great majority of cases (Alkan, et 
al 1995, Swerdlow, et al 1995) and false negativity is usually related to poor fixation or 
inadequate antigen retrieval (Fu, et al 2005). In cases with equivocal staining, 
immunohistochemistry (IHC) for the neuronal transcription factor SOX11 and fluorescence in 
situ hybridization (FISH) for IGH/CCND1 should be added (Dictor, et al 2009, Ek, et al 2008, 
Remstein, et al 2000, Sander, et al 2007, Soldini, et al 2014).  An aberrant 
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immunophenotype, such as CD5 negativity or expression of CD10, BCL6 or CD23, occurs in 
5–18% of cases and may lead to an erroneous diagnosis (Camacho, et al 2004, Espinet, et 
al 2010, Gualco, et al 2010, Schlette, et al 2003, Wlodarska, et al 1999, Zanetto, et al 2008),  
Flow Cytometry (peripheral blood or bone marrow): typically, MCL expresses CD19, CD20, 
CD79b, CD22, CD5 and FMC7 with moderately intense expression of surface light chains, 
more commonly lambda (Bertoni, et al 1999). CD10 expression is seen in a small proportion 
of cases, particularly in those with blastoid morphology (Zanetto, et al 2008). Although cyclin 
D1 expression cannot be assessed by flow cytometry, SOX11 expression is detectable and 
may assist in distinguishing CLL from MCL on peripheral blood samples (Wasik, et al 2015). 
Lack of expression of CD200 in MCL in contrast to CLL (Spacek 2014) may also 
discriminate between these entities.  
Cyclin D1-negative MCL 
Genuine cyclin D1-negative cases of MCL lacking the IGH/CCND1 rearrangement have 
been recognized through gene expression profiling and are rare (Fu, et al 2005, Herens, et 
al 2008, Quintanilla-Martinez, et al 2009). The cytomorphology, immunophenotype (other 
than cyclin D1 negativity) and clinical course are identical to cases of classical MCL. The 
lymphoma is characterized by a rearrangement of CCND2 in 55% of cases (Salaverria, et al 
2013). Some cases involve CCND3. SOX11 is expressed within the nucleus of almost all 
cyclin D1-negative cases enabling this entity to be reliably identified (Carvajal-Cuenca, et al 
2012, Ek, et al 2008, Mozos, et al 2009). Immunocytochemistry for SOX11 should be added 
in all cases of CD5-positive/cyclin D1-negative B-cell lymphoma.  
In situ MCL 
This rare entity is characterised by the presence of CD5+ cyclinD1+ small lymphocytes in 
the mantle zone of the follicle in a morphologically reactive lymph node (Richard, et al 2006). 
In a recent study, only one of 12 patients with in situ MCL developed clinically overt disease 
over a follow-up period of four years (Carvajal-Cuenca, et al 2012). In view of the non-
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progressive nature of this entity in the majority of cases, it has been renamed as mantle cell 
neoplasia (ISMCN) in the recent update of the WHO lymphoma classification (Swerdlow, et 
al 2016) 
Indolent MCL 
There are two types of indolent MCL. The first presents with limited stage disease, displays 
the typical morphology and immunophenotype of classical MCL, often with a nodular or 
mantle zone pattern and has a very low proliferation fraction. It tends to be SOX11- and 
cyclin D1-positive (Jares, et al 2012, Saeow 2016). The second type presents as a 
leukaemia with splenomegaly and lack of (or low volume) lymphadenopathy. It has highly 
mutated IGHV genes, a simple karyotype, kappa (rather than lambda) restriction and absent 
or low SOX11 expression (Fernandez, et al 2010, Nodit, et al 2003, Ondrejka, et al 2011). It 
is associated with an indolent course although transformation may occur, which may be the 
first indication of a diagnosis of MCL (Kiel and Smith 2012). 
 
Genetics and molecular diagnostics 
The characteristic cytogenetic abnormality of MCL is the t(11;14)(q13.3;q32.33) 
translocation, resulting in overexpression of cyclin D1 contributing to deregulated cell cycle 
progression at the G1-S phase boundary (Vandenberghe, et al 1991, Williams, et al 1993). 
In practice, the translocation, which is usually detected by FISH on fresh or FFPE tissue 
(Belaud-Rotureau, et al 2002, Dubus, et al 2002, Reichard, et al 2006), should be 
demonstrated in cases with atypical morphology, an aberrant immunophenotype, equivocal 
cyclin D1 positivity or unusual clinical presentation. Secondary cytogenetic abnormalities are 
common in MCL and the degree of karyotypic complexity is negatively associated with 
patient survival (Cuneo, et al 1999) (Katzenberger, et al 2008, Parry-Jones, et al 2007, 
Wlodarska, et al 1999). The majority of MCL cases are characterised by an unmutated IGHV 
gene. A small proportion possess a highly mutated IGHV gene that is most commonly seen 
Author’s final draft of a paper accepted for publication in British Journal of Haematology 2018 DOI 
10.1111/bjh.15281. 
in the indolent leukaemic group with low or absent expression of SOX11 (Nodit, et al 2003). 
A detailed account of the molecular pathogenesis of MCL can be found in several recent 
review articles (Campo and Rule 2015, Dreyling, et al 2015, Jares, et al 2012, Vose 2013).  
Biological prognostic factors 
 Many biological features have been examined such as growth pattern, blastoid morphology, 
TP53 expression, IGHV gene mutation status and secondary cytogenetic abnormalities with 
varying reports as to their significance (Argatoff, et al 1997, Jares, et al 2012, Katzenberger, 
et al 2006, Nordstrom, et al 2014, Norton, et al 1995, Ott, et al 1997). Identification of 
blastoid morphology may be difficult in view of variation in fixation and the subjective nature 
of assessing cell size. Proliferative activity by Ki67 index is the most important prognostic 
factor in routine diagnostic practice (Determann, et al 2008, Katzenberger, et al 2006, 
Tiemann, et al 2005) with an index of >30% associated with a poorer outcome. 
Inter-observer variability in assessment of the proliferation index is well recognized. The 
European MCL Network suggest that counting the Ki67 positive cells among 100 lymphoma 
cells in each of two representative high-power fields generates improved consistency 
(Klapper, et al 2009). 
TP53 mutations predict a very poor outcome that appears not to be overcome by intensive 
up front therapy in younger patients (Eskelund, et al 2017). In patients with true leukaemic 
(non-nodal) disease, SOX11 negativity can help predict an indolent phenotype but this does 
not apply in nodal disease. Kappa rather than lambda restriction may indicate indolent 
disease (see above).  CD23 expression is also detected in this group by flow cytometry 
(Ondrejka, et al 2011). None of these factors is currently robust enough to serve as a basis 
for modification of treatment.  
 
Differential diagnosis 
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Cyclin D1 may be expressed in a number of other lymphoproliferative disorders, such as 
hairy cell leukaemia, multiple myeloma and 3% of DLBCL (Ehinger, et al 2008). Adequate 
assessment of morphology and an appropriate panel of immunocytochemistry  should 
prevent erroneous diagnosis. In the case of DLBCL, lack of a demonstrable IGH/CCND1 
translocation and lack of immunoreactivity for SOX11 differentiates this group from 
pleomorphic variants of MCL (Hsiao, et al 2012).  
 
Recommendations 
• Lymph node excision or adequate core biopsy is required for the diagnosis of 
nodal mantle cell lymphoma (MCL). In a non-nodal presentation, tissue biopsy 
or peripheral blood may provide the diagnosis.  
• All cases should be subject to routine central review by an experienced 
haematopathologist.  
• Immunohistochemical panels for the investigation of all B cell lymphomas 
should include cyclin D1.  
• SOX11 immunostaining is required for the diagnosis of cyclin D1-negative 
MCL and should be included in panels where there is a suspicion of MCL.  
• The presence of the t(11;14) translocation should be demonstrated by 
fluorescence in situ hybridization in cases with atypical morphology, aberrant 
immunophenotype, equivocal cyclin D1 positivity or unusual clinical 
presentation. 
•  It is recommended that the Ki67 Proliferation Index be recorded at baseline, 
with an index of > 30% suggestive of poorer outcome.  
 
Initial Investigations, Staging and Prognostic Scores 
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      Laboratory investigations: 
Full blood count and blood film  
Immunophenotyping by flow cytometry if peripheral blood lymphocytosis is seen (20-
40% of patients)  
Biochemical investigations including lactate dehydrogenase (LDH) 
Virology - it is recommended that patients undergo testing for hepatitis B (surface 
antigen and core antibody), hepatitis C and human immunodeficiency virus (HIV) 
prior to therapy  
Bone marrow aspirate and trephine biopsy – recommended for staging. May be 
omitted in the presence of peripheral blood involvement or, if flow cytometry is 
available, to assess marrow involvement in aspirate sample, trephine biopsy may be 
avoided  
Lumbar puncture and cytological examination of cerebrospinal fluid by cytospin, 
together with flow cytometry should be performed if there is any clinical suspicion of 
CNS disease.  
 
Imaging in MCL 
Computed tomography (CT) of the neck, chest, abdomen and pelvis should be performed 
(contrast-enhanced unless contraindicated). Magnetic resonance imaging (MRI) may be 
useful for assessment of CNS disease where clinical suspicion is high (Ferrer, et al 2008, 
Gill, et al 2009, Gill and Seymour 2008). (18F) Fluorodeoxyglucose positron emission 
tomography (FDG-PET) is now used in the assessment of many types of lymphoma. It has 
been shown that MCL is FDG-avid, particularly the blastoid variant and nodal disease 
(Brepoels, et al 2008). However, in contrast to other lymphomas, FDG-PET has been shown 
to have lower sensitivity in staging MCL, particularly extranodal disease and has not been 
shown to upstage compared with CT scan (Hosein, et al 2011). Routine use of FDG-PET for 
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this purpose cannot currently be recommended outside the context of a clinical trial. 
Although the role of FDG-PET in early stage MCL remains unproven, it may be considered if 
radical radiotherapy is being proposed. 
 
Endoscopy – some authorities recommend routine colonoscopy and upper gastro-intestinal 
(GI) endoscopy as part of staging investigations in MCL (Zelenetz& Hoppe, 2001), on the 
basis that prospective studies have identified microscopic involvement by MCL of the GI 
tract in 92% of cases (Salar et al, 2006). This finding rarely (less than 4% of cases) changes 
clinical management (Romaguera, et al 2003). Endoscopy should be performed on the basis 
of clinical symptoms, particularly in those patients with features of GI bleeding or if clinical 
stage 1A disease is present and radiotherapy with curative intent is planned. Where 
endoscopy is performed, biopsies of any suspicious lesions, and also macroscopically 
normal areas, should be taken for histological examination.  
 
Pregnancy testing in women of childbearing age prior to chemotherapy  
 
Staging 
The modified Ann Arbor staging system (Lister et al 1989) is used. As most patients with 
MCL have blood and bone marrow involvement at presentation, clinical stage in isolation is 
not of great prognostic significance.  
 
Clinical prognostic scoring systems 
The international prognostic index (IPI) is not reliable in MCL (Hoster, et al 2008, Moller, et al 
2006). A prognostic scoring system specifically for MCL, the MCL international prognostic 
index (MIPI) has been devised (Hoster, et al 2008). A simplification of this score (sMIPI) 
assigns patients to three groups (low, intermediate and high risk) according to values of four 
clinical variables: age, Eastern Cooperative Oncology Group performance status, serum 
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LDH and white blood cell count. The combined MIPI (MIPI-c) (Hoster, et al 2016), which also 
includes Ki-67 index, refines the prognostic score further by dividing patients into four 
groups: low, low-intermediate, high-intermediate or high risk. The sMIPI and MIPI-c can be 
calculated on line at http://www.european-mcl.net/en/clinical_mipi.php. Whilst these 
scores provide clear prognostic information, they do not usually influence treatment 




• Performance status should be recorded at baseline  
• Routine blood tests including full blood count and film, and biochemical tests 
including lactate dehydrogenase should be performed  
• Virological testing for hepatitis B, hepatitis C and human immunodeficiency 
virus is recommended prior to immunochemotherapy  
• Patients should undergo staging bone marrow aspirate and trephine biopsy 
unless there is peripheral blood involvement; trephine may be avoided if flow 
cytometry is carried out on aspirate sample 
• Patients should undergo clinical staging with computed tomography of neck, 
chest, abdomen and pelvis 
• Routine use of (18F) Fluorodeoxyglucose positron emission tomography in the 
staging or response assessment of MCL is not recommended 
• Colonoscopy and other endoscopy should only be performed for clinical 
indications, or if radiotherapy for stage IA disease is considered 
• Lumbar puncture with cytospin and immunophenotyping if clinical suspicion 
of central nervous system involvement 
• All patients should have their simplified or combined MCL international 
prognostic index (sMIPI or MIPI-c, respectively) score recorded at baseline 
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